SOUTH SAN FRANCISCO, Calif., Dec. 20, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications (the Company), today announced the pricing of an underwritten public offering of 1,105,263 shares of its common stock, offered at a price of $9.50 per share to the public. The gross proceeds to the Company from this offering are expected to be approximately $10.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. All of the shares in the offering are to be sold by the Company. The offering is expected to close on or about December 22, 2017, subject to the satisfaction of customary closing conditions.

JonesTrading Institutional Services LLC and Ladenburg Thalmann & Co. Inc. are acting as Joint Book-running Managers and LifeSci Capital LLC is acting as a Co-Manager for the proposed offering.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (SEC) and is effective. A final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s web site at www.sec.gov. When available, copies of the final prospectus supplement may also be obtained from JonesTrading Institutional Services LLC, 32133 Lindero Canyon Road, Suite 208, Westlake Village, CA 91361, Attention: Compliance Department, or via telephone at (844) 566-6587 or via email at [email protected]

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein. There shall not be any offer, solicitation of an offer to buy, or sale of securities in any state or jurisdiction in which such an offering, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Print Friendly, PDF & Email